Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis

Abstract

Background Immunocompromised (IC) patients are at higher risk of severe SARS-CoV-2 infection, morbidity, and mortality compared to the general population. They should be prioritized for primary prevention through vaccination. This study aimed to evaluate the efficacy of COVID-19 mRNA vaccines in IC patients through a systematic review and meta-analysis approach. Method PubMed-MEDLINE, Scopus, and Web of Science were searched for original articles reporting the immunogenicity of two doses of mRNA COVID-19 vaccines in adult patients with IC condition between June 1, 2020 and September 1, 2021. Meta-analysis was performed using either random or fixed effect according to the heterogeneity of the studies. Subgroup analysis was performed to identify potential sources of heterogeneity. Results A total of 26 studies on 3207 IC patients and 1726 healthy individuals were included. The risk of seroconversion in IC patients was 48% lower than those in controls (RR = 0.52 [0.42, 0.65]). IC patients with autoimmune conditions were 54%, and patients with malignancy were 42% more likely to have positive seroconversion than transplant recipients (P < 0.01). Subgroup meta-analysis based on the type of malignancy, revealed significantly higher proportion of positive seroconversion in solid organ compared to hematologic malignancies (RR = 0.88 [0.85, 0.92] vs. 0.61 [0.44, 0.86], P = 0.03). Subgroup meta-analysis based on type of transplantation (kidney vs. others) showed no statistically significant between-group difference of seroconversion (P = 0.55). Conclusions IC patients, especially transplant recipients, developed lower immunogenicity with two-dose of COVID-19 mRNA vaccines. Among patients with IC, those with autoimmune conditions and solid organ malignancies are mostly benefited from COVID-19 vaccination. Findings from this meta-analysis could aid healthcare policymakers in making decisions regarding the importance of the booster dose or more strict personal protections in the IC patients.

Adverse outcome and severity of COVID ‐19 in patients with autoimmune bullous diseases: A historical cohort study

“…This finding suggests that although the underlying disease and immunosuppressive medications might reduce the immunogenicity of the vaccine, it can still prevent more severe cases. 37 All immunocompromised dermatology patients should be vaccinated against SARS‐CoV‐2, and clinicians should consider future vaccine schedule when prescribing immunotherapeutic agents. 38 , 39 It is preferred to vaccinate AIBD patients in remission phase of disease to boost its efficacy and lower the risk of disease flare post vaccine.…”

Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis

“…Therefore, the mRNA vaccine could be suitable as an option for immunosuppressed patients ( 6 ). Previous cumulative data on the efficacy and safety of mRNA vaccines have been collected in immunosuppressed patients ( 14 ), and in patients with hematological malignancies by Cavanna et al. ( 15 ) and Sakuraba et al.…”

Chest CT Scan Features to Predict COVID-19 Patients’ Outcome and Survival

“…Although all patients were treated based on a unique national protocol, minor treatment differences based on physician clinical judgment could affect mortality and survival, which were not assessed in the present study. This study was conducted before the national COVID-19 vaccination program and further investigations on a larger population after vaccination are recommended to confirm our findings [ 28 ].…”